They include a pegylated interferon-alpha-2b, in development for the bone marrow disorder polycythemia vera, and a dendritic cell therapy for treating glioblastoma, which its subsidiary Activartis Biotech GmbH, also of Vienna, is developing. (See BioWorld Today, April 10, 2003.) Market Diversification Newbridge, based in Dubai, in the United Arab Emirates, is an earlier-stage venture

Sangamo BioSciences Inc., of Richmond, Calif., said data demonstrating the successful application of its in vivo protein replacement platform (IVPRP) to produce therapeutically relevant levels of Factor VIII in a mouse model were presented at the annual meeting of the American Society of Gene and Cell Therapy

They include a pegylated interferon-alpha-2b, in development for the bone marrow disorder polycythemia vera, and a dendritic cell therapy for treating glioblastoma, which its subsidiary Activartis Biotech GmbH, also of Vienna, is developing. (See BioWorld Today, April 10, 2003.) Market Diversification Newbridge, based in Dubai, in the United Arab Emirates, is an earlier stage venture

The Advanced Therapy Access Program for experimental treatments with the company's oncolytic viruses was made possible through European Union (EU) regulation EC/1394/2007, designed to improve safe access by patients across the EU to gene therapy, somatic cell therapy and tissue-engineered products that were not yet commercially available. (See BioWorld International, Sept. 6, 2006, and Nov. 1, 2006.) Under the experimental program, 290 patients from 20 countries were treated with the company's

Cellular Biomedicine Group Inc., of Palo Alto, Calif., achieved 50 percent enrollment of the total projected enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of human adipose-derived mesenchymal progenitor cells therapy for knee osteoarthritis

The data were presented by researchers from Nuvo and the Fraunhofer Institute for Cell Therapy and Immunology IZI at the annual meeting of the American Association of Immunologists in Honolulu

Nuvo Research Inc., of Mississauga, Ontario, said researchers from the Fraunhofer Institute for Cell Therapy and Immunology IZI and Nuvo presented data on its immune-modulating drug candidate, WF10, including its therapeutic impact on signs and symptoms of experimentally induced rheumatoid arthritis in mice at the 100th Annual Meeting of The American Association of Immunologists in Honolulu

Sangamo BioSciences Inc., of Richmond, Calif., said it presented new clinical data, which demonstrated that SB-728-T treatment resulted in a reduction in the HIV reservoir in HIV-infected subjects, at the 16th Annual Meeting of the American Society of Gene and Cell Therapy in Salt Lake City

Kite is developing cancer immunotherapeutic products with a focus on engineered autologous T-cell therapy

Dallas-based Gradalis offered the interim results at the Annual Meeting of the American Society of Gene and Cell Therapy in Salt Lake City, in an oral presentation titled, "Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG) for High Risk III/IV Ovarian Cancer: Preliminary Results

As with many other trials of stem cell therapies in cardiac disease, the trial is not sufficiently large to be powered for mortality only, the key measure of any cardiac therapy's efficacy...The precise mechanisms by which stem cell therapies in cardiac disease operate remain controversial

Company (Location) Product Description Indication Status Date AUTOIMMUNE Biogen Idec Inc. (Weston, Mass.) DAC HYP A daclizumab high-yield process Multiple sclerosis Phase IIb data showed it reduced the annualized relapsed rate by 54%, meeting the study's primary endpoint 4/5/13 Fibrocell Science Inc. (Exton, Pa.) LaViv Autologous fibroblast injection azficel-T Moderate-to-severe acne scars Phase II study demonstrated that azficel-T treatment was associated with clinically meaningful improvement

cells therapy Knee osteoarthritis Started a Phase I trial 4/4/13 RESPIRATORY Admacure Ltée (Quebec City) ASM-024 Dry powder for inhalation formulation Asthma Started a Phase I/II trial 4/16/13 MISCELLANEOUS Advanced Cell Technology Inc. (Santa Monica, Calif.) hESC Human embryonic stem cell-derived retinal pigment epithelial cells Macular degeneration Treated patients in a third cohort of each of its two Phase I trials 4/2/13 American Biotech Labs LLC (Salt Lake City) Nanosilver particle Silver

The typical goal of stem cell therapies is to get the mature cells they produce to take up permanent residence in patients

Cardio3 BioSciences closed a $25 million investment round to fund an ongoing European Phase III trial of its stem cell therapy for ischemic heart failure

As with many other trials of stem cell therapies in cardiac disease, the trial is not sufficiently large to be powered for mortality only, the key measure of any cardiac therapy's efficacy...The precise mechanisms by which stem cell therapies in cardiac disease operate remain controversial

The technology is being developed to aid in understanding the biology critical to cardiac tissue engineering, for applications in regenerative cell therapy for heart disease and for predictive use in vitro assays for drug rescue and development

Emerging victorious were Daniela Couto, CEO of Cell2B, a cell therapy firm based in Portugal, and Donn Rubin, president and CEO of the BioSTL Coalition, a collaborative group fostering innovative life sciences programs in St. Louis

The split was undertaken to allow the firm to list on the NYSE MKT, and the autologous cell therapy company said it has been cleared to submit a listing application